Neue Therapien kutaner T-Zell-Lymphome

Zusammenfassung

Kutane Lymphome gehören zu den seltenen Erkrankungen. Sie stellen eine heterogene Gruppe mit sehr unterschiedlicher klinischer Symptomatik und Prognose dar. Aufgrund der Komplexität der Erkrankung ist die Einbeziehung eines spezialisierten Zentrums empfehlenswert.

Wir stellen im Folgenden drei Patienten mit primär kutanen T-Zell-Lymphomen (CTCL) aus unserem Hauttumorzentrum vor. Anhand dieser Fallbeispiele möchten wir die multimodale Therapie von CTCL unter Berücksichtigung neu zugelassener Medikamente für diese Indikation beschreiben.

Abstract

Cutaneous lymphomas belong to the rare diseases. They represent a heterogeneous group with very different clinical symptoms and prognosis. Due to the complexity of the disease, the involvement of a specialized center is recommended.

In the following, we present three patients with primary cutaneous T-cell lymphomas (CTCL) from our skin cancer center. Based on these case studies, we would like to describe the multimodal therapy of CTCL, taking into account newly approved drugs for this indication.

Publication History

Article published online:
09 December 2022

• Literatur

• 1 Willemze R, Cerroni L, Kempf W. et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714 DOI: 10.1182/blood.2019002852.
• 2 Dippel E, Assaf C, Becker JC. et al. S2k Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021. J Deutsche Derma Gesell 2022; 20: 537-555 DOI: 10.1111/ddg.14706_g.
• 3 Olsen E, Vonderheid E, Pimpinelli N. et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722 DOI: 10.1182/blood-2007-03-055749.
• 4 Scarisbrick JJ, Hodak E, Bagot M. et al. Blood classification and blood response criteria in mycosis fungoides and Sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer 2018; 93: 47-56 DOI: 10.1016/j.ejca.2018.01.076.
• 5 Moore DC, Elmes JB, Shibu PA. et al. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas. Ann Pharmacother 2020; 54: 371-379 DOI: 10.1177/1060028019884863.
• 6 Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Science 2006; 97: 1139-1146 DOI: 10.1111/j.1349-7006.2006.00307.x.
• 7 Remer M, Al-Shamkhani A, Glennie M. et al. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy 2014; 6: 1187-1206 DOI: 10.2217/imt.14.94.
• 8 POTELIGEO, Kyowa Kirin, Fachinformation.
• 9 Kim YH, Bagot M, Pinter-Brown L. et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet Oncology 2018; 19: 1192-1204 DOI: 10.1016/S1470-2045(18)30379-6.
• 10 O’Malley JT, de Masson A, Lowry EL. et al. Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res 2020; 26: 408-418 DOI: 10.1158/1078-0432.CCR-18-4147.
• 11 Lessin SR, Duvic M, Guitart J. et al. Topical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides. JAMA Dermatol 2013; 149: 25 DOI: 10.1001/2013.jamadermatol.541.
• 12 Kim EJ, Geskin L, Guitart J. et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. Journal of the American Academy of Dermatology 2020; 83: 928-930 DOI: 10.1016/j.jaad.2019.12.070.
• 13 Assaf C, Booken N, Dippel E. et al. Chlormethin Gel zur Behandlung der Mycosis fungoides: Ein Expertenkonsens aus Deutschland, Österreich und der Schweiz (DACH Region) zum Therapiemanagement. J Deutsche Derma Gesell 2022; 20: 579-588 DOI: 10.1111/ddg.14688_g.
• 14 Prince HM, Kim YH, Horwitz SM. et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet 2017; 390: 555-566 DOI: 10.1016/S0140-6736(17)31266-7.
• 15 Horwitz SM, Scarisbrick JJ, Dummer R. et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Advances 2021; 5: 5098-5106 DOI: 10.1182/bloodadvances.2021004710.
• 16 Blazejak C, Stranzenbach R, Gosman J. et al. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network. Dermatology 2022; 238: 498-506 DOI: 10.1159/000517830.